Vanguard Group Inc. lowered its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 2.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,580,967 shares of the life sciences company's stock after selling 162,961 shares during the period. Vanguard Group Inc. owned about 9.82% of Integra LifeSciences worth $171,936,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Nisa Investment Advisors LLC increased its position in Integra LifeSciences by 599.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after purchasing an additional 2,800 shares during the period. Empowered Funds LLC purchased a new position in Integra LifeSciences during the fourth quarter valued at approximately $180,000. Centiva Capital LP bought a new position in Integra LifeSciences in the third quarter worth approximately $192,000. Mitsubishi UFJ Asset Management UK Ltd. purchased a new stake in Integra LifeSciences during the fourth quarter worth $204,000. Finally, Romano Brothers AND Company bought a new stake in Integra LifeSciences during the 4th quarter valued at $204,000. 84.78% of the stock is currently owned by institutional investors.
Integra LifeSciences Stock Performance
Shares of Integra LifeSciences stock traded down $0.43 during midday trading on Friday, hitting $16.99. The company had a trading volume of 659,615 shares, compared to its average volume of 1,049,936. The company has a fifty day simple moving average of $22.28 and a 200 day simple moving average of $22.31. The stock has a market cap of $1.31 billion, a price-to-earnings ratio of -188.76, a PEG ratio of 0.73 and a beta of 1.24. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a 12-month low of $15.97 and a 12-month high of $33.04.
Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business had revenue of $442.65 million during the quarter, compared to the consensus estimate of $445.15 million. During the same period in the previous year, the firm posted $0.89 earnings per share. The business's revenue for the quarter was up 11.5% compared to the same quarter last year. As a group, analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several research analysts have recently commented on the company. Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Truist Financial reduced their target price on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a report on Friday. Three analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company. According to MarketBeat, Integra LifeSciences has a consensus rating of "Hold" and a consensus price target of $22.71.
Check Out Our Latest Research Report on IART
About Integra LifeSciences
(
Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Recommended Stories
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
